IndraLab

Statements

SB 203580 inhibits NFKBIA. 7 / 8
| 2 5
reach
"To establish a role of p38 in IkappaB-alpha degradation, C6 cells were treated with 10 muM SB203580 for 1 h and then co-treated with SB203580, 100 ng/mL TNF-alpha and 50 ng/mL IL-1beta."
18679050
eidos
"Liu et al. reported that SB203580 inhibited the degradation of IkappaBalpha , confirming the involvement of p38 in NF-kappaB activation [ 57 ] ."
33424977
eidos
"In addition , a specific p38 MAPK inhibitor , SB203580 , blocked IkappaBalpha degradation ."
34114391
reach
"However, salusin-beta treatment resulted in the obvious up-regulation of NF-kappaBp65 and down-regulation of I-kappaBalpha (P < 0.05, P < 0.01, XREF_FIG), which was antagonized by SB203580 and SP600125 (P < 0.05, P < 0.01)."
25210730
reach
"The p38 mitogen activated protein (MAP) kinase inhibitor SB203580 prevented stabilization of IkappaBalpha and delayed the re-emergence of IkappaBalpha following TNF-alpha-induced degradation."
12704657
reach
"Microinjection of p38 inhibitor SB203580 into the NAc prior to the application of morphine prevented the acquisition of CPP and inhibited the activation of p38, IkappaB-alpha and NF-kappaB p65."
21130118
reach
"In addition, a specific p38 MAPK inhibitor, SB203580, blocked IkappaBalpha degradation."
34114391